Pacira Q3 Net Income Jumps to $28.5M as Viatris Tender Offer Runs
PCRX sits 94% above its 52-week low of $18.8.
Summary
Pacira reported Q3 net income of $28.5 million ($0.70 diluted) on $176.7 million of revenue, closed the iovera sale for $73.6 million, and disclosed two stockholder suits seeking to block the pending $36.50-per-share Viatris merger.
Key Events · Earnings and Guidance · PCRX
-
Q3 Net Income Rises to $28.5M
Net income was $28.5 million, or $0.70 per diluted share, versus $5.4 million ($0.12) a year earlier, lifted by a $14.4 million non-cash contingent-consideration gain and a $6.6 million divestiture gain.
-
Revenue Slips 2% to $176.7M
Total Q3 revenue fell 2% to $176.7 million as iovera dropped out after the July 31 sale; EXPAREL rose 2% to $142.5 million and ZILRETTA 3% to $29.8 million. Nine-month revenue was $546.4 million, up 3%.
-
iovera Sale Closed for $73.6M
The Zimmer divestiture closed July 31, 2026, delivering $73.6 million in cash plus up to $70.0 million of revenue-based milestones through 2031.
-
Two Suits Challenge Merger Disclosures
Complaints filed November 2 and 3, 2026 in New York Supreme Court allege the October 30 Schedule 14D-9 omitted material information and seek to enjoin the merger until it is disclosed; Pacira has not been served.
Analysis · PCRX · Life Sciences
Pacira's Q3 results show the underlying business holding up while the $36.50-per-share Viatris tender offer runs: net income rose to $28.5 million ($0.70 diluted) from $5.4 million a year ago, helped by a $14.4 million non-cash contingent-consideration gain and a $6.6 million gain on the closed iovera divestiture. Revenue slipped 2% to $176.7 million as iovera dropped out of the base, but EXPAREL grew 2% and ZILRETTA 3%. The bigger new item is governance: two stockholder suits filed November 2-3 allege the Schedule 14D-9 omitted material information and seek to block the merger until it is disclosed. With the deal expected to close before year-end, the operating numbers matter less than whether the tender clears and the litigation is contained.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.